Cleanroom Technology’s Post

Throwing it back to our first Life Science Seminar of 2024. Industry experts gathered to dive deep into the differences between Biology and Chemistry labs. Our moderator, Greg McClure of Delawie, expertly guided the discussion, featuring panelists Mike Barbera of ISPE and Intersect Management, James Bassett of Arrowhead Pharmaceuticals, and Jamie Prevost of Prevost Construction. We learned so much from their expertise and discussions. Thanks to everyone who joined us and special thanks to sponsors ABM and San Diego Mechanical Energy! Stay tuned for more exciting events targeting the Life Science sector. #LifeScienceSeminar #LifeScience #IndustryExperts #BOMASD #ThrowbackThursday

📢 Only one week away! Dive into the latest in chemical synthesis! Join us for an insightful SpiroWebinar where we explore cutting-edge strategies in synthetic chemistry. 📅 June 19th, 2024 – Prof. Kevin Brown & Quentin Lefebvre, PhD Topic: Covering a new chemical space with atom-economical synthesis and functionalization of sp3-rich scaffolds Register here: https://lnkd.in/dYbS_RFC Moderator: Priya Kalia, PhD – Managing Director at SciTribe. What we'll cover: Despite shortcomings in terms of ADME properties, sp2-rich compounds are prevalent in drug discovery programs, while sp3-rich scaffolds are much less represented despite their relevance in medicinal chemistry, possibly due to the lack of efficient synthetic methods. In this webinar, we will show how we use novel synthetic strategies to access conformationally rigid, sp3-rich scaffolds with diverse exit vectors, either by photoinduced de-novo synthesis from flat molecules, or by C-H functionalization of already elaborated sp3-rich molecules. Learn more: https://lnkd.in/dTXrBVNe #SpiroWebinars #SpiroTeam #SpiroChem #DrugDiscovery #OrganicChemistry #sp3Innovation #ChemicalSynthesis #sp3Scaffolds #MedicinalSynthesis #CHFunctionalization #DrugDesign

We cannot quite believe that there are only 2 weeks to go until we return to Boston, US to run our '6th Flow Chemistry and Continuous Processing Conference' on May 2-3. The team are just sorting out the final arrangements and we cannot wait to see you all. If you have not yet registered to attend, come and join us in Boston. You will get to meet our amazing panel of speakers (pictured below). You will have the opportunity to ask questions after each session and join in at our 'Discussion Session' covering some of the hottest topics in continuous processing. Our conference will also feature two keynote presentations;- The first Keynote Presentation will be delivered by Professor Tim Jamison from #MIT, USA. Tim will be discussing 'On-Demand Synthesis through the Lens of Flow Chemistry.' Professor C. Oliver Kappe and Dr Peter Sagmeister will be our second Keynote Speakers on Friday May 3 and they will be discussing 'The Rocky Road to a Digital (Flow Chemistry) Lab'. Don’t miss out on this opportunity to become part of our flow chemistry community! The networking events include our speakers, sponsors and other delegates - and these events are all aimed at fostering collaboration and knowledge exchange. Please visit our website to find out more and to register at https://lnkd.in/ePspr8GZ #FLOWNA24 #FlowChemistry #Flow #ContinuousProcessing #Pharma #FineChemicals #Sustainability #OrganicChemistry #Expo #Networking #DiscussionSession  

Checkout the PIPETMAN® G Single-Channel Metal Ejector Pipettes by Gilson — available now at 39% OFF during our Summer Sale! Ergonomic, precise, and durable, perfect for reliable lab work. 🐸🔬💧 LEARN MORE: https://hubs.li/Q02zk9tx0 The PIPETMAN® G Single-Channel Metal Ejector Pipettes by Gilson offer ergonomic comfort, high accuracy, and durability. These pipettes reduce hand fatigue with lower pipetting forces and feature a robust metal ejector for long-lasting use, making them ideal for molecular biology, clinical diagnostics, and chemical analysis applications. SHOP SUMMER SALE: https://hubs.li/Q02zk9vs0 VIEW SALE FLYER: https://hubs.li/Q02zk9xj0 📆 Sale Ends: June 14th, 2024 #FroggaBio #PIPETMAN #SummerSale #LabEquipment #Pipettes #LiquidHandling #ErgonomicDesign #LabTools #ScientificResearch #ClinicalDiagnostics #MolecularBiology #ChemicalAnalysis #PrecisionPipetting #AccurateResults #Laboratory #ScienceEquipment #LabLife #ResearchTools #Biotech #Pharma #Healthcare #QualityControl #LabInnovation #ScientificTools #LabTech #LifeSciences #LabWork #Science #Research #TechInLab

#5 Wolff rearrangement In the annals of chemistry, few have left as indelible a mark as Ludwig Wolff, a German chemist whose work has resonated through the corridors of time, influencing not just academic circles but also the very fabric of the pharmaceutical industry. Wolff's academic career was a testament to his brilliance and dedication. He was known for his rigorous approach to research and an insatiable curiosity that drove him to explore the intricate dance of atoms and molecules. His work was pioneering, laying the groundwork for future chemists to build upon. Among his numerous contributions, the Wolff rearrangement stands out as a beacon of his ingenuity. The Wolff Rearrangement, a chemical reaction that involves the rearrangement of α-diazoketones to ketenes, is a cornerstone in synthetic organic chemistry. This process has become a vital tool for chemists, enabling the synthesis of complex molecules from simpler precursors. In today's pharmaceutical landscape, the Wolff rearrangement plays a critical role in the synthesis of various compounds, including antibiotics and anti-inflammatory drugs. Its ability to efficiently create ketenes, which can be readily transformed into a plethora of functional groups, makes it invaluable in the design and development of new drugs. The flexibility and versatility offered by this rearrangement have enabled chemists to innovate and create more effective and targeted therapies, improving patient outcomes and contributing to the advancement of medicine. The Wolff rearrangement is a reminder of his genius, a gift to the realms of chemistry and medicine that has propelled the pharmaceutical industry into new frontiers. As we look to the future, Wolff's legacy serves as both a cornerstone and a beacon, guiding ongoing efforts to unravel the mysteries of chemistry and harness them for the betterment of humanity.

🎓What were you doing in 2004? I was an undergraduate in chemistry, finishing up a placement year in the lab at a pharmaceutical company. It was where I was introduced to analytical techniques, and I just loved piecing together all the clues that enabled the identification and characterization of small molecule drugs and impurities. It was during my time in industry that I attended a special event. A team from an analytical instrumentation company had come in to talk about their new, game-changing technology. They told us that work that took 10 minutes could now be done in 2 minutes. They shared some mind-blowing data. The audience was sceptical. There were whispers of "it will never catch on". But there was also an air of excitement. It was several year later that it occurred to me I had attended a launch presentation for the ACQUITY UPLC, from Waters Corporation. The company I joined in 2011. And did it catch on? You bet. With over 300 million hours and 27 million liters of mobile phase saved, and referenced in more than 25,000 publications, UPLC changed industry expectations for analysis and continues to set the standard today. So, dear network - where were you in 2004? How to participate: 1. Post a picture of yourself from 2004 and give a little background about what you were doing back then…use the hashtag #20YearsofUPLCpic 2. Share how the innovation of UPLC impacted you then, and now. 3. Nominate your colleagues and friends to participate. Marleen van Wingerden, Bàrbara Bagó, Sam Read, Scott Rudland MRSC and James Hallam - you're up!

Last week, our R&D team in Chasse-sur-Rhône (France) showcased recent case studies on optimizing APIs and intermediates. Highlights included a multistep synthesis for an Antibody-Drug Conjugate (#ADC) linker and a continuous flow process for an unstable intermediate. 🔎 𝑹𝒐𝒃𝒖𝒔𝒕𝒏𝒆𝒔𝒔 was the key theme, with the team demonstrating process reliability and precision with statistical tools. 🎯 With a 24% increase in yield and a 63% improvement in Process Mass Intensity (PMI) in crystallization, we eliminated the need for recrystallization while enhancing both productivity and sustainability. This session also fostered collaboration, exploring innovations like online crystallization monitoring and a wet milling step for targeted Particle Size Distribution. ⭐ At Axplora, we go beyond reacting — we seek answers in new places, respond with agility, and redefine partnerships to deliver life-changing treatments faster. #R&D #Innovation #ADC #FlowChemistry

We are at Drug Discovery Chemistry 2024! ✨ Stop by booth 314 to meet our President of the Americas, Marc Neglia. Don't forget to swing by and check out our poster, "Complete Thermal Melting Characterization of the NISTmAb with the SUPR-DSF Microplate Reader," during the poster sessions. 📖 Learn More: https://lnkd.in/e5QXzWSw. #DrugDiscoveryChemistry #SmallMoleculeCharacterization #ProteinStability

I missed it until today (Published: 11 January 2024) From none other than Bob Langer and Nicholas Peppas. I was actually looking to see if the the US-Japan Symposium on Drug Delivery Systems is back on or not. A bright future in medicine for chemical engineering " Controlled-release systems deliver a drug at a pre-determined rate for a finite time and/or can target drugs to specific organs or tissues. " #RobertLanger, and Nicholas Peppas "A bright future in medicine for chemical engineering." Nature Chemical Engineering 1.1 (2024): 10-12. Please note that there is a Competing interests document citing 190 organizations. Don't worry - no doubts on integrity here. #BiomedicalEngineering #ChemicalEngineering #DrugDelivery

In this edition of our #ArdenaExpertInsights series, we turn our attention to the importance of Design of Experiments (DoE) in API crystallization process development. Laura Spix, Senior Scientist and Group Leader in Solid State Research at Ardena, discusses how DoE offers a structured, statistical method to tackle challenges such as polymorphic form selection, particle size distribution, and critical process parameters. Through DoE, we can optimize crystallization conditions, reduce trial-and-error, and ensure consistent, high-quality results. Explore how Ardena utilizes DoE to enhance experimental design and improve outcomes in API crystallization, using advanced equipment and analytical techniques. Read the full Q&A below and stay tuned for more insights from our experts on key drug development topics!. #Ardena #DesignOfExperiments #DoE #APIcrystallization #DrugDevelopment #ArdenaExperts